Clinical trials: Obese Subjects
Obesity
Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity
The purpose of this study is determine if the combination of zonisamide SR and bupropion SR are is more effective than either drug given alone or placebo in the treatment of obesity.
- Trial name
- NCT00709371
- Testing
- Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day
- Where
- 20 sites in United States
- Volunteers
- 729 people
- Sponsor
- Orexigen Therapeutics, Inc
Healthy
A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects
This study is designed to compare the pharmacokinetics of three different formulations of Pf-04937319
- Trial name
- NCT01513928
- Testing
- Pf-04937319
- Where
- Singapore
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypertension, Concurrent Obesity
Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects
This study investigated the effects of LCZ696 on insulin sensitivity, lipolysis, and oxidative metabolism in obese hypertensive subjects.
- Trial name
- NCT01631864
- Testing
- LCZ696, amlodipine
- Where
- 3 sites in Germany, Netherlands
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
COLOMBES Project:Constitution of a Population-based Cohort of Obese Subjects With Longitudinal Long-term Follow-up
The objective of the project is the constitution of a population-based cohort of 500 persons with severe or morbid obesity (BMI over 35 kg/m2) with annual follow-up for 10 years.
- Trial name
- COLOMBES (NCT00632671)
- Where
- France
- Volunteers
- 311 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy Subjects
A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose…
- Trial name
- NCT07102251
- Testing
- HEC-007 injection
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Overweight or Obesity
Multicenter Trial Investigating Performance and Safety of the Medical Device SiPore21®
The present clinical investigation is a randomized, double-blinded, placebo-controlled, multicenter international trial, planned to be conducted in Poland, Romania and Slovakia.
- Trial name
- SHINE (NCT06087822)
- Testing
- IMD SiPore21®
- Where
- 27 sites in Poland, Romania and 1 more
- Volunteers
- 318 people
- Sponsor
- Sigrid Therapeutics AB
Bacterial Infections, Obesity
Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile
The purpose of this study is to better understand how clindamycin works in children who fall in the 85th percentile or higher for body mass index (BMI - a ratio of weight to height).
- Trial name
- CLIN01 (NCT01744730)
- Testing
- Clindamycin
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Phillip Brian Smith
Weight Loss, Obesity
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
Exenatide is an incretin-like drug that has been approved for treatment of type 2 diabetes; it improves glycemia by increasing insulin and decreasing glucagon secretion by pancreatic islet cells and delaying gastric emptying.
- Trial name
- NCT00856609
- Testing
- Byetta (exenatide), Weight loss, Metabolic Chamber
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Overweight and Obesity
A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
This is a study of HS-20094 in participants with overweight and obesity. The main purpose is to learn more about how HS-20094 affects body weight.
- Trial name
- NCT06118021
- Testing
- HS-20094
- Where
- 2 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Obesity
Anti-obesity Treatment by Loading in Adult Subjects
Obesity related ailments, such as cardiovascular diseases (CVD) and metabolic disorders are major causes of death in the Western World.
- Trial name
- ATLAS (NCT04697238)
- Testing
- Weight vest
- Where
- Sweden
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Lipid Metabolism Disorders
Stearidonic Acid and Lipid Metabolism
Evidence exists that EPA (eicosapentaenoic acid or C20:5n-3) supplementation can reduce the risk for coronary heart disease. EPA can be synthesized from α-linolenic acid (ALA or C18:3n-3), but conversion is low.
- Trial name
- NCT01365078
- Testing
- Echium oil (SDA-rich oil), high-oleic acid sunflower oil (HOSO) (low in SDA)
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Overweight, Obesity
Efficacy and Safety of Glucosanol in Maintaining Body Weight
To date, there is no clinical evidence on the efficacy and safety of Glucosanol in maintaining weight loss beyond the study duration of 12 weeks.
- Trial name
- NCT01435278
- Testing
- Glucosanol
- Where
- Germany
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Metabolism and Nutrition Disorder, Overweight or Obesity
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants…
- Trial name
- STEP 1 (NCT03548935)
- Testing
- Semaglutide
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 1,961 people
- Sponsor
- Novo Nordisk A/S
Obese
A Study of Distal Jejunal-release Dextrose in Obese Participants
The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose [Aphaia technology, AT]) in obese participants.
- Trial name
- NCT05385978
- Testing
- APHD-012, APHD-012P
- Where
- 9 sites in Georgia, Germany and 1 more
- Volunteers
- 150 people
- Sponsor
- Aphaia Pharma US LLC
Safety and Tolerability
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
The trial is a Phase 1, single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial including three cohorts in Part 1 in a semi-parallel design and one cohort in Part 2…
- Trial name
- NCT06000891
- Testing
- ZP7570
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Obesity, Overweight and Obesity
A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight
This is a 24 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase IIb trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased…
- Trial name
- NCT06606483
- Testing
- MDR-001
- Where
- 19 sites in China
- Volunteers
- 300 people
- Sponsor
- MindRank AI Ltd
Overweight, Obesity
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety, tolerability and effect on body weight of a range of doses of metreleptin and pramlintide, each administered by a separate subcutaneous…
- Trial name
- NCT00673387
- Testing
- pramlintide acetate, metreleptin
- Where
- 36 sites in United States
- Volunteers
- 636 people
- Sponsor
- AstraZeneca
Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity
This is a multicenter, randomized, double-blind, placebo-controlled, parallel design phase II clinical trial, including a screening period of up to 2 weeks, a 36-weeks' treatment period, and a 1-week safety follow-up visit period.
- Trial name
- NCT06820099
- Testing
- HRS-7535 tablet
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obesity
A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.
This Study is a Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects.
- Trial name
- NCT06481098
- Testing
- HM15275
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
This trial is conducted in the United States of America (USA). The aim of this trial is to determine the dose-response relationship for body weight and five escalating doses of NNC 90-1170 (liraglutide) in subjects with type 2…
- Trial name
- NCT01511198
- Testing
- liraglutide, metformin
- Where
- 39 sites in United States
- Volunteers
- 223 people
- Sponsor
- Novo Nordisk A/S